Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma
Authors:
- Michael LeinMLMichael Lein
- Manfred JohannsenMJManfred Johannsen
- Mark SchraderMSMark Schrader
- Kurt MillerKMKurt Miller
- Stefan A. LoeningSLStefan A. Loening
- Klaus JungKJKlaus Jung
- 1 September 2008
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 269 (1) , 85-92
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populationsLaboratory Investigation, 2007
- Evaluation of Serum Amyloid A as a Biomarker for Gastric CancerAnnals of Surgical Oncology, 2006
- Diagnostic and Prognostic Validity of Serum Bone Turnover Markers in Metastatic Renal Cell CarcinomaJournal of Urology, 2006
- Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patientsLaboratory Investigation, 2004
- Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinomaCancer, 2004
- Metastatic renal cell carcinomaCurrent Treatment Options in Oncology, 2003
- Growth rates of primary and metastatic lesions of renal cell carcinomaInternational Journal of Urology, 2001
- Localized renal cell carcinomaCurrent Treatment Options in Oncology, 2001
- Serum Amyloid A Protein (SAA) in Colorectal CarcinomaClinical Chemistry and Laboratory Medicine (CCLM), 2001